drugset / Trial / NCT02549196

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

NCT02549196

Non-randomizedSingle-groupSingle-blindTreatment

Summary

This is a Phase II, ascending dose study of CPC-201 in patients with dementia of Alzheimer's type to determine the optimal dose titration schedule.

Timeline

Start
2015-10-07
Primary completion
2017-09-28
Completion
2017-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 40 mg
Subject Donepezil Small molecule 60 mg
Subject Solifenacin Small molecule 15 mg
Subject Solifenacin Small molecule 20 mg

Indications